» Articles » PMID: 26135631

Cantharidin Represses Invasion of Pancreatic Cancer Cells Through Accelerated Degradation of MMP2 MRNA

Overview
Journal Sci Rep
Specialty Science
Date 2015 Jul 3
PMID 26135631
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Cantharidin is an active constituent of mylabris, a traditional Chinese medicine, and is a potent and selective inhibitor of protein phosphatase 2A (PP2A) that plays an important role in cell cycle control, apoptosis, and cell-fate determination. In the present study, we found that cantharidin repressed the invasive ability of pancreatic cancer cells and downregulated matrix metalloproteinase 2 (MMP2) expression through multiple pathways, including ERK, JNK, PKC, NF-κB, and β-catenin. Interestingly, transcriptional activity of the MMP2 promoter increased after treatment with PP2A inhibitors, suggesting the involvement of a posttranscriptional mechanism. By using an mRNA stability assay, we found accelerated degradation of MMP2 mRNA after treatment of cantharidin. Microarray analyses revealed that multiple genes involved in the 3' → 5' decay pathway were upregulated, especially genes participating in cytoplasmic deadenylation. The elevation of these genes were further demonstrated to be executed through ERK, JNK, PKC, NF-κB, and β-catenin pathways. Knockdown of PARN, RHAU, and CNOT7, three critical members involved in cytoplasmic deadenylation, attenuated the downregulation of MMP2. Hence, we present the mechanism of repressed invasion by cantharidin and other PP2A inhibitors through increased degradation of MMP2 mRNA by elevated cytoplasmic deadenylation.

Citing Articles

Shuganning Injection Suppresses Apoptosis for Protecting Against Cantharidin-Induced Liver Injury by Network Pharmacology and Experiment Validation.

Duan X, Ao J, Yu M, Li S, Li X, Zhang J ACS Omega. 2024; 9(12):13692-13703.

PMID: 38559921 PMC: 10976354. DOI: 10.1021/acsomega.3c07981.


Hepatotoxic mechanism of cantharidin: insights and strategies for therapeutic intervention.

Jin D, Huang N, Wei J Front Pharmacol. 2023; 14:1201404.

PMID: 37383714 PMC: 10293652. DOI: 10.3389/fphar.2023.1201404.


Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality.

van Pelt J, Meeusen B, Derua R, Guffens L, Van Cutsem E, Janssens V J Transl Med. 2023; 21(1):317.

PMID: 37170215 PMC: 10176933. DOI: 10.1186/s12967-023-04145-z.


Ribosome-Directed Therapies in Cancer.

Temaj G, Chichiarelli S, Eufemi M, Altieri F, Hadziselimovic R, Farooqi A Biomedicines. 2022; 10(9).

PMID: 36140189 PMC: 9495564. DOI: 10.3390/biomedicines10092088.


Cantharidin downregulates PSD1 expression and inhibits autophagic flux in yeast cells.

Swagatika S, Tomar R FEBS Open Bio. 2021; 12(5):1017-1035.

PMID: 33999504 PMC: 9063437. DOI: 10.1002/2211-5463.13196.


References
1.
Lee J, Lee J, Trembly J, Wilusz J, Tian B, Wilusz C . The PARN deadenylase targets a discrete set of mRNAs for decay and regulates cell motility in mouse myoblasts. PLoS Genet. 2012; 8(8):e1002901. PMC: 3431312. DOI: 10.1371/journal.pgen.1002901. View

2.
Bartlam M, Yamamoto T . The structural basis for deadenylation by the CCR4-NOT complex. Protein Cell. 2011; 1(5):443-52. PMC: 4875137. DOI: 10.1007/s13238-010-0060-8. View

3.
Ito H, Duxbury M, Benoit E, Clancy T, Zinner M, Ashley S . Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res. 2004; 64(20):7439-46. DOI: 10.1158/0008-5472.CAN-04-1177. View

4.
Zhang A, Liu W, Yan Y . Role of the RRM domain in the activity, structure and stability of poly(A)-specific ribonuclease. Arch Biochem Biophys. 2007; 461(2):255-62. DOI: 10.1016/j.abb.2007.02.023. View

5.
Guerra C, Schuhmacher A, Canamero M, Grippo P, Verdaguer L, Perez-Gallego L . Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell. 2007; 11(3):291-302. DOI: 10.1016/j.ccr.2007.01.012. View